Management of treatment-resistant obsessive-compulsive disorder: An update on therapeutic strategies

Annals of Indian Academy of Neurology

Volumn 10, Issue 3, 2007, Pages 145-153

  Mishra, Biswaranjan ^a,b   Sahoo, Saddichha ^a   Mishra, Baikunthanath ^a  

^a CENTRAL INSTITUTE OF PSYCHIATRY   (India)

^b SCB MEDICAL COLLEGE   (India)

Author keywords

Obsessive compulsive disorder; Treatment resistant obsessive compulsive disorder

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CITALOPRAM; CLOBAZAM; CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; CLOZAPINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PHENELZINE; PIMOZIDE; PINDOLOL; PLACEBO; QUETIAPINE; RILUZOLE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUMATRIPTAN; TRAZODONE; TRYPTOPHAN; VENLAFAXINE;

AMNESIA; ANXIETY DISORDER; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DELUSIONAL DISORDER; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; EOSINOPHILIA MYALGIA SYNDROME; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FORGETFULNESS; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HEART DISEASE; HUMAN; HYPERTENSIVE CRISIS; INSOMNIA; INTOXICATION; IRRITABILITY; LOW DRUG DOSE; MEDLINE; MONOTHERAPY; MOOD DISORDER; NEUROSURGERY; NEUROTOXICITY; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIAPISM; PSYCHOSIS; PSYCHOTHERAPY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REHABILITATION CARE; REVIEW; RISK FACTOR; SEDATION; SEROTONIN SYNDROME; SIDE EFFECT; TARDIVE DYSKINESIA; TIC; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE; TRICHOTILLOMANIA; VAGUS NERVE STIMULATION; WEIGHT GAIN; XEROSTOMIA;

EID: 34948860053     PISSN: 09722327     EISSN: None     Source Type: Journal    
DOI: 10.4103/0972-2327.34793     Document Type: Review

References (119)

1. International Classification of Diseases 10 Classification of Mental and Behavioral Disorders Diagnostic Criteria for Research, World Health Organization: Geneva; 1993.
2. Zohar J, Insel TR. Obsessive-compulsive disorder: Psychobiological approaches to diagnosis, treatment and pathophysiology. Biol Psychiatry 1987;22:667-87.
3. Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: Preclinical and clinical evidence. J Clin Psychiatry 2004;65:11-7.
4. Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. Arch Gen Psychiatry 1991;48:730-8.
5. Goodman WK, McDougle CJ, Price LH. Pharmacotherapy of obsessive-compulsive disorder. J Clin Psychiatry 1992,53:29-37.
6. Jenike MA, Rauch SL. Managing the patient with treatment-resistant obsessive-compulsive disorder: Current strategies. J Clin Psychiatry 1994;55:11-7.
7. McDougle CJ, Goodman WK, Leckman JF, Barr LC, Heninger GR, Price LH. The efficacy of fluvoxamine in obsessive-compulsive disorder: Effects of comorbid chronic tic disorder. J Clin Psychopharmacol 1993;13:354-8.
8. McDougle CJ, Goodman WK, Leckman JF, Price LH. The psychopharmacology of obsessive-compulsive disorder Implications for treatment and pathogenesis. Psychiatr Clin North Am 1993;15:749-66.
9. Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder: A meta analytic review. Br J Psychiatry 1995;166:424-43.
10. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999;60:101-6.
11. Rasmussen SA, Eisen JL, Pato MT. Current issues in the pharmacologic management of obsessive-compulsive disorder. J Clin Psychiatry 1993;54:4-9.
12. Hollander E, DeCaria CM, Schneier FR, Schneier HA, Liebowitz MR, Klein DF. Fenfluramine augmentation of serotonin reuptake blockade anti obsessional treatment. J Clin Psychiatry 1990;51:119-23.
13. National Institute for Clinical Excellence (NICE) guidelines Manual-Chapter 7:Reviewing and grading the evidence (2007). Available from: http://www.nice.org.uk
14. Goodman WK, Price LH. Assessment of severity and change in obsessive-compulsive disorder. Psychiatr Clin North Am 1992;15:861-9.
15. Skoog G, Skoog I. A 40-year follow-up of patients with obsessive-compulsive disorder. Arch Gen Psychiatr 1999;56:441-2.
16. Perugi G, Akiskal HS, Gemingnani A, Pfanner C, Presta S, Milanfranchi A, et al. Episodic course in obsessive-compulsive disorder. Eur Arch Psychiatr Clin Neurosci 1998;248:240-4.
17. Ravizza L, Maina G, Bogetto F. Episodic and chronic obsessive-compulsive disorder. Depress Anxiety 1997;6:154-8.
18. Rasmussen SA, Eisen JL. Treatment strategies for chronic and refractory obsessive-compulsive disorder. J Clin Psychiatry 1997;58:9-13.
19. Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: Methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:400-12.
20. Guy W. ECDEU: Assessment manual for psychopharmacology. US Dept of Health, Education and Welfare: Washington DC; 1976. p. 76:338.
21. Walsh KH, McDougle CJ. Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder. Expert Opin Pharmacother 2004;5:2059-67.
22. Pallanti S, Hollander E, Goodman WK. A qualitative analysis of non response: Management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry 2004;65:6-10.
23. Rapoport JL. The waking nightmare: An overview of obsessive-compulsive disorder. J Clin Psychiatry 1990;51:25-8.
24. rd ed. St Louis, MO: Mosby, Inc; 1998.
25. Gershuny BS, Baer L, Jenike MA, Minichiello WE, Wilhelm S. Comorbid posttraumatic stress disorder: Impact on treatment outcome for obsessive-compulsive disorder. Am J Psychiatry 2002;159:852-4.
26. Mellman TA, Uhde TW. Obsessive-compulsive symptoms in panic disorder. Am J Psychiatry 1987;144:1573-6.
27. Eisen JL, Beer DA, Pato MT, Venditto TA, Rasmussen SA. Obsessive-compulsive disorder in patients with schizophrenia or schizoaffective disorder. Am J Psychiatry 1997;154:271-3.
28. O'Dwyer AM, Marks I. Obsessive-compulsive disorder and delusions revisited. Br J Psychiatry 2000;176:281-4.
29. Montgomery SA, Kasper S, Stein DJ, Bang Hedegaard K, Lemming OM. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001;16:75-86.
30. Thiel A, Broocks A, Ohleimer M, Jacoby G, Schubler G. Obsessive-compulsive disorder among patients with anorexia nervosa and bulimia nervosa. Am J Psychiatry 1995;152:72-5.
31. Cavedini P, Erzegovesi S, Ronchi P, Bellodi L. Predictive value of obsessive compulsive personality disorder in anti-obsessional pharmacological treatment. Eur Neuropsychopharmacol 1997;7:45-9.
32. Baer L, Jenike MA, Black DW, Treece C, Rosenfeld R, Greist J. Effect of axis II diagnoses on treatment outcome with clomipramine in 55 patients with obsessive-compulsive disorder. Arch Gene Psychiatry 1992;49:862-6.
33. Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983;40:605-12.
34. Greist JH, Jefferson JW, Rosenfeld R, Gutzmann LD, March JS, Barklage NE. Clomipramine and obsessive-compulsive disorder: A placebo-controlled double-blind study of 32 patients. J Clin Psychiatry 1990;51:292-7.
35. Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 1980;37:1281-5.
36. Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 1996;169:468-74.
37. Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. Arch Gen Psychiatry 1990;47:926-32.
38. Freeman CP, Trimble MR, Deakin JF, Stokes TM, Ashford JJ. Fluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: As multicentre, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994;55:301-5.
39. Hollander E, Fay M, Liebowitz MR. Clonidine and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1988;145:388-9.
40. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1997;154:396-401.
41. Fallon BA, Liebowitz MR, Campeas R, Schneier FR, Marshall R, Davies S, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: A placebo-controlled study. Arch Gene Psychiatry 1998;55:918-24.
42. Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol 1993;3:143-52.
43. Tollefson GD, Rampey AH Jr, Potvin JH, Jenike MA, Rush AJ, Kominguez RA, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559-67.
44. Bergeron R, Ravindran A, Chaput Y, Goldner E, Swinson R, van Ameringen MA, et al. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: Results of a double-blind, 6-month treatment study. J Clin Psychopharmacol 2002;22:148-54.
45. Romano S, Goodman W, Tamura R, Gonzalez J. Long-term treatment of obsessive-compulsive disorder after an acute response: A comparison of fluoxetine versus placebo. J Clin Psychopharmacol 2001;21:46-52.
46. Nulman I, Koren G. The safety of fluoxetine during pregnancy and lactation. Tratology 1996;53:304-8.
47. Goodman WK, Kozak MJ, Liebowitz M, White KL. Treatment of obsessive-compulsive disorder with fluvoxamine: A multicentre, double-blind, placebo-controlled trial. Int J Clin Psychopharmacol 1996;11:21-9.
48. Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, et al. A double blind, placebo controlled study of the efficacy and safety of controlled release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 2003;64:640-7.
49. Greist JH, Jefferson JW, Kobak KA, Chouinard G, DuBoff E, Halaris A, et al. A 1 year double blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int J Clin Psychopharmacol 1995;10:57-65.
50. Chouinard G. Sertraline in the treatment of obsessive-compulsive disorder: Two double-blind, placebo-controlled studies. Int Clin Psychopharmacol 1992;7:37-41.
51. Koran L, Hackett E, Rubin A, Wolkow R, Robinson D. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry 2002,159:88-95.
52. Hollander E, Allen A, Steiner M, Wheadon D, Oakes R, Burnham DB, et al. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 2003;64:1113-21.
53. Denys D, vanderWee N, vanMegen HJ, Westenberg HG. A double blind comparison of venlafaxine and paroxetine in obsessivecompulsive disorder. J Clin Psychopharmacol 2003;23:568-75.
54. Denys D, van Megen HJ, van der Wee N, Westenberg HG. A double blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 2004;65:37-43.
55. Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine and citalopram in the treatment of obsessive-compulsive disorder: A single-blind study. J Clin Psychopharmacol 1997;17:267-71.
56. Bareggi SR, Bianchi L, Cavallaro R, Gervasoni M, Siliprandi F, Bellodi L. Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results. CNS Drugs 2004;18:329-35.
57. Pallanto S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: An open trial. J Clin Psychiatry 2002;63:796-801.
58. Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol 2002;22:309-17.
59. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry 1995;52:53-60.
60. Bascher NM. Clonazepam treatment of obsessive-compulsive disorder. J Clin Psychiatry 1990;51:168-9.
61. Bodkin JA, White K. Clonazepam in the treatment of obsessive-compulsive disorder associated with panic disorder in one patient. J Clin Psychiatry 1989;50:265-6.
62. Jenike MA, Baer L, Buttolph L. Buspirone augmentation of fluoxetine in patients with obsessive-compulsive disorder. J Clin Psychiatry 1991;52:13-4.
63. Markovitz PJ, Stagno SJ, Calabrese JR. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry 1990;147:798-800.
64. Pigott TA, L'Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL. A double-blind study of adjuvant buspirone hydrochloride in clomipramime-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:11-8.
65. Eisenberg J, Asnis G. Lithium as an adjunct treatment in obsessive-compulsive disorder. Am J Psychiatry 1985;142:663.
66. McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR. A controlled trial of lithium augmentation in fluvoxamine refractory obsessive-compulsive disorder: Lack of efficacy. J Clin Psychopharmacol 1991;11:175-84.
67. Pigott TA, Pato MT, L'Heureux F, Hill JL, Grover GN, Bernstein SE, et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1991;11:242-8.
68. Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): A 12 week open trial. Psychiatry Res 2000;96:91-8.
69. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, et al. Neuroleptic addition in fluvoxamine refractory obsessive-compulsive disorder. Am J Psychiatry 1990;147:652-4.
70. Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandeli J, Nordlie J, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1989;46:722-30.
71. Stein DJ, Bouwer C, Hawkridge S, Emsley RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997;58:119-22.
72. Stein DJ, Hollander E. Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J Clin Psychiatry 1992;53:123-6.
73. McDougle CT, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A, et al. Lack of efficacy of clozapine monotherapy in refractory obsessive disorder. Am J Psychiatry 1995;152:1812-4.
74. Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment-resistant obsessive-compulsive disorder: A single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002;17:115-9.
75. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302-8.
76. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, et al. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990;147:652-4.
77. Stein DJ, Hollander E. Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J Clin Psychiatry 1992;53:123-6.
78. Judd FK, Chua P, Lunch C, Norman T. Fenfluramine augmentation of clomipramine treatment of obsessive-compulsive disorder. Aust N Z J Psychiatry 1991;25:412-4.
79. Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996;153:1219-21.
80. Jenike MA, Baer MA, Minichiello WE, Rauch LS, Buttolph ML. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 1997;154:1261-4.
81. Barr LC, Goodman WK, Anand A, McDougle CJ, Price LH. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry 1997;154:1293-5.
82. Grossman R, Hollander E. Treatment of obsessive-compulsive disorder with venlafaxine. Am J Psychiatry 1996;153:576-7.
83. Hollander E, Friedberg J, Wasserman S, Allen A, Birnbaum M, Konen L. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2003;64:546-50.
84. Stern L, Zohar J, Cohen R, Sasson Y. Treatment of severe, drug resistant obsessive-compulsive disorder with the 5HT agonist sumatriptan. Eur Neuropsychopharmacol 1998;8:325-8.
85. Peterson BS, Cohen DJ. The treatment of Tourette's syndrome: Multimodal, developmental intervention. J Clin Psychiatry 1998,59:62-74.
86. Treatment of obsessive-compulsive disorder. The Expert Consensus Panel for obsessive-compulsive disorder. J Clin Psychiatry 1997;58:2-72.
87. Jenike MA, Surman OS, Cassem NH, Zusky P, Anderson WH. Monoamine oxidase inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1983;44:131-2.
88. Hohagen F, Winkelmann G, Rasche-Rüchle H, Hand I, König A, Münchau N, et al. Combination of behavior therapy with fluvoxamine in comparison with behavior therapy and placebo: Results of multicentre study. Br J Psychiatry 1998;35:71-8.
89. Simpson HB, Gorfinkel KS, Liebowitz MR. Cognitive behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: An open trial. J Clin Psychiatry 1999;60:584-90.
90. Treatment of obsessive-compulsive disorder. Expert Consensus Panel for Obsessive-Compulsive Disorder. J Clin Psychiatry 1997;58:3-28.
91. th ed. Wiley: New York; 1994. p. 428-66.
92. nd ed. Oxford University Press: New York; 2002.
93. rd ed. Jenike MA, Baer L, Minichiello WE, editors. Mosby Publishing: St. Loius, MO; 2002. p. 611-24.
94. Hohagen F, Winkelmann G, Rasche-Ruchle H, Hand I, König A, Münchau N, et al. Combination of behavior therapy with fluvoxamine in comparison with behavior therapy and placebo. Results of a multicentre study. Br J Psychiatry Suppl 1998; 35:71-8.
95. Hembree EA, Riggs DS, Kozak MJ, Franklin ME, Foa EB. Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder. CNS Spectrums 2003;8:363-81.
96. rd ed. Jenike MA, Baer L, Minichiello WE, editors. Mosby Publishing: St. Loius, MO; 2002. p. 368-90.
97. Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006;3:69-81.
98. Jenike MA. An update on obsessive-compulsive disorder. Bull Menninger Clin 2001;65:4-25.
99. Maletzky B, McFarland B, Burt A. Refractory obsessive-compulsive disorder and ECT. Convuls Ther 1994;10:34-42.
100. Beale MD, Kellner CH, Pritchett JT, Burns CM. ECT for OCD. J Clin Psychiatry 1995;56:81-2.
101. Husain MM, Lewis SF, Thornton WL. Maintenance ECT for refractory obsessive-compulsive disorder. Am J Psychiatry 1993;150:1899-900.
102. Alonso P, Pujol J, Cardoner N, Benlloch L, Deus J, Menchón JM, et al. Right prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: A double-blind, placebo-controlled study. Am J Psychiatry 2001;158:1143-5
103. Sachdev PS, McBride R, Loo CK, Mitchell PB, Malhi GS, Croker VM. Right versus left prefrontal transcranial magnetic stimulation for obsessive-compulsive disorder: A preliminary investigation. J Clin Psychiatry 2001;62:981-4.
104. Greenberg BD, George MS, Martin JD, Benjamin J, Schlaepfer TE, Altemus M, et al. Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: A preliminary study. Am J Psychiatry 1997;154:867-9.
105. Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS). Int J Neuropsychopharmacol 2006;9:95-100.
106. Lopez CA, de Mathis ME, Canteras MM, Salvajoli JV, Del Porto JA, Miguel EC. Update on neurosurgical treatment for obsessive-compulsive disorder. Rev Bras Psiquiatr 2004;26:61-6.
107. Baer L, Rauch SL, Ballantine HT, Martuza R, Cosgrove R, Cassem E, et al. Cingulotomy for interactable obsessive-compulsive disorder: Prospective long-term follow-up of 18 patients. Arch Gen Psychiatry 1995;52:384-92.
108. Jenike MA, Baer L, Ballantine T, Martuza RL, Tynes S, Giriunas I, et al. Cingulotomy for refractory obsessive-compulsive disorder: A long-term follow-up of 33 patients. Arch Gen Psychiatry 1991;48:548-55.
109. Dougherty DD, Baer L, Cosgrove GR, Cassem EH, Price BH, Nierenberg AA, et al. Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder. Am J Psychiatry 2002;159:269-75.
110. rd ed. Mosby, Inc: St Louis, MO; 1998.
111. Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, et al. Refractory obsessive-compulsive disorder: State of the art treatment. J Clin Psychiatry 2002;63:20-9.
112. Matthews K, Eljamel M. Status of neurosurgery for mental disorder in Scotland. Selective literature review and overview of current clinical activity. Br J Psychiatry 2003;182:404-11.
113. st Annual Meeting of the American Association of Neurological Surgeons, San Diego, April 28, 2003
114. Mindus P, Jenike MA. Neurosurgical treatment of obsessive-compulsive disorder. Psychiatr Clin North Am 1992;15:921-38.
115. National Institute of Mental Health, Deep Brain Stimulation for Treatment-Resistant Obsessive-compulsive disorder, NCT00057603. Accessed at John Hopkins University Hospital
116. Marks IM, Hodgson R, Rachman S. Treatment of chronic OCD by in vivo exposure. Br J Psychiatry 1975;127:349-64.
117. Watts FN, Bennett DH. Rehabilitation in neurotic, affective and conduct disorder, Theory and practice of psychiatric rehabilitation. Wiley Publishers: NY, USA; 1991. p. 65-80.
118. Schruers K, Koning K, Luermans J, Haack MJ, Griez E. Obsessive-compulsive disorder: A critical review of therapeutic perspectives. Acta Psychiatr Scand 2005;111:261-71.
119. st annual meeting, Phoenix (Arizona) May 28-31.